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Introduction 
Bronchodilators have beneficial effects in the treatment of 
COPD (1). Although the most commonly used bronchodi- 
lators, anticholinergics and pz-agonists, have been com- 
pared in many clinical studies, there is still debate as to 
which drug is the most effective. 
Anticholinergics 
Ipratropium bromide is the most commonly used anti- 
cholinergic in COPD, though oxitropium bromide is used 
in some countries. A more long-acting anticholinergic drug, 
tiotropium bromide, is due to become clinically available in 
the near future (2-6). 
MECHANISMS OF ACTION 
Anticholinergics have been used as bronchodilators for 
several hundred years in western Europe (7). They act by 
blocking the effects of acetylcholine, which is released from 
parasympathetic nerves in the airways, and which con- 
tributes to bronchoconstriction and mucus secretion in 
patients with COPD. Acetylcholine causes activation of 
muscarinic receptors at the level of the target cells, such as 
brochial smooth muscle and goblet cells (8). Muscarinic Ml 
receptors are present in parasympathetic ganglia in the 
bronchial wall, and M2 receptors are found pre-junction- 
ally on post-ganglionic cholinergic nerves. The most 
important receptor for the effects of acteylcholine is, 
however, the M3 receptor, because M3 receptor blockade 
will reduce all cholinergic bronchoconstrictor responses (9). 
EFFECTS OF ANTICHOLINERGICS 
Inhaled ipratropium bromide leads to bronchodilation and 
has a slightly slower onset of action than salbutamol, but a 
slightly longer duration of effect (10). It is important to 
remember that anticholinergics will reverse only one 
endogenous mediator of airflow obstruction, that is the 
release of acetylcholine from nerves, and will not affect 
bronchoconstriction induced by other mediators. It is, 
therefore, possible that functional antagonists of bronchial 
smooth muscle contraction, such as &agonists, will result 
in more pronounced bronchodilatation, because they 
reduce the adverse effects of several mediators in the 
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airways. This statement is supported by the results of 
several published studies (11-l 3). 
Anticholinergics are more effective in patients with 
COPD than in those with asthma, probably because 
parasympathetic tone contributes to the airway narrowing 
to a substantial degree in COPD (14,15). Nevertheless, the 
maximal bronchodilating effect of a &agonist is still more 
pronounced in most studies and, more importantly, p2- 
agonists are much more effective in improving bronchial 
responsiveness in patients with COPD (15-l 7). 
P2-agonists 
The relatively short-acting inhaled P2-agonists, salbutamol 
and terbutaline, have been used in the management of 
COPD for many years. In the recent guidelines published 
by the Global Initiative for Chronic Obstructive Lung 
Diseases (GOLD) (1) inhaled short-acting Pz-agonists, 
either alone or in combination with anticholinergics, are 
recommended as an alternative to the use of anticholiner- 
gics alone in the treatment of COPD (1,18). 
The most important recent improvement in bronchodi- 
lator treatment has been the introduction of two long- 
acting inhaled &agonists, salmeterol and formoterol (19- 
21,22-24), both of which have proved to be beneficial in 
COPD (1). The duration of action of both drugs exceeds 
12 h on average, compared with 4-5 h for salbutamol and 6 h 
for ipratropium bromide. Salmeterol was developed for use 
by inhalation, but formoterol was initially developed as an 
oral bronchodilator, and was subsequently shown to have a 
far longer duration of action when administered by 
inhalation than by the oral route (21). Interestingly, 
formoterol has been shown to be more effective than 
ipratropium bromide in a large population of patients with 
COPD (25), particularly in terms of quality of life. The 
different pharmacological properties of ipratropium bro- 
mide and formoterol may explain these findings. 
MECHANISMS OF ACTION 
At the Pz-receptor, a /&-agonist forms hydrogen bonds to 
specific amino acids within the receptor protein, and thus 
induces a change in the three-dimensional structure of the 
receptor. This process enables the receptor to interact with 
intracellular stimulatory G-proteins (Gs) (26-28) which in 
turn stimulate the production of intracellular cyclic 
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adenosine monophosphate (CAMP) (29). Production of 
CAMP leads to activation of protein kinase A (PKA), which 
leads to the phosphorylation of several intracellular 
proteins, resulting eventually in bronchial smooth muscle 
relaxation by inhibition of myosin-actin interaction (30). 
Other mechanisms of action of /&agonists that are 
independent of CAMP have been proposed, including K+- 
channel activation via a sub-unit of the Gs (31-35). 
Importantly, &agonists are functional antagonists. Thus, 
they cause relaxation of the smooth muscle, regardless of 
which stimulus is causing the contraction. 
airways after inhalation, move rapidly through the tissue to 
quickly reach the smooth muscle layer and its &receptors. 
Formoterol is not as lipophilic as salmeterol, and therefore 
a substantial proportion of formoterol molecules remain in 
the water phase and move rapidly through the airway wall 
(37,38,45), which may explain its more rapid onset of action 
(40,46). The long duration of action of both formoterol and 
salmeterol can be explained by the fact that both drugs are 
stored in the cell membrane lipid bilayer (Fig. 2) primarily 
in the smooth muscle, in close proximity to the Pz-receptor. 
This allows the lipophilic long-acting &agonists to be 
available to the receptor over a long period of time (37,45). 
EFFECTS OF &-AGONISTS 
The pharmacological behaviour of salmeterol and formo- 
terol has several similarities, but also some clear differences. 
Both drugs are lipophilic (Fig. I), though salmeterol is 
more lipophilic than formoterol (3638). In airway smooth 
muscle preparations, the onset of action of salmeterol is 
slower than both salbutamol and formoterol, whereas the 
onset of action of formoterol is as rapid as salbutamol (39- 
41). However, salmeterol and formoterol have very similar 
durations of action in patients with asthma, despite the fact 
that formoterol has a slightly shorter duration of action 
than salmeterol in vitro (4&43). 
An additional mechanism has been proposed to explain 
the long duration of action of salmeterol. It has been 
suggested that the long lipophilic arm of salmeterol 
interacts with a specific binding region within the p2- 
receptor. This reduces the likelihood of salmeterol leaving 
the receptor and enables the active portion of the salmeterol 
molecule to re-engage with the active site of the receptor 
region (the anchored-binding hypothesis) (45,4749). How- 
ever, the addition of excessive amounts of the salmeterol 
side chain, which according to pharmacological principles 
should block the binding of salmeterol to this anchored- 
binding site, does not influence the duration of effect of 
salmeterol (50). This argues against the anchored binding 
hypothesis for salmeterol. 
MICROKINETIC DIFFUSION THEORY FULL Vs. PARTIAL AGONISM 
The mechanisms of action of formoterol and salmeterol at 
the tissue and receptor level are considered to be quite 
different to those of the short acting /&agonists. Anderson 
(44) has suggested that lipophilicity may be the most 
important factor in explaining why formoterol and 
salmeterol behave differently when given by inhalation. 
Because of its very high lipophilicity, salmeterol passes very 
rapidly into different cell membranes in the airway wall, 
and the cell membranes of all cells are likely to work as a 
depot of salmeterol (44) (Fig. 2). This is likely to reduce the 
speed by which salmeterol will reach the smooth muscle 
layer and the functional j32-receptors, because it will first 
enter other (non-smooth muscle) cells. In contrast, the more 
water soluble &agonists, such as salbutamol, which are 
present in high concentrations in the water phase of the 
Salmeterol and formoterol also differ in efficacy (their 
maximal effect). Salmeterol has been shown to be a partial 
agonist. Although salmeterol has some intrinsic activity at 
the P2-receptor level, it does not have the ability to fully 
reverse a severe smooth muscle contraction, unlike the 
more effective &agonists, such as salbutamol or formoter- 
ol(42). Formoterol is a full agonist, and has been shown to 
be more effective and have a greater maximal effect than 
salmeterol in vivo (51) (Fig. 3). 
In a randomized, double-blind study of patients with 
asthma, high doses of formoterol were shown to confer 
greater protection against methacholine-induced broncho- 
constriction than salmeterol (51). The maximal broncho- 
protective effect of salmeterol, 250 pg, was approximately 
2.5 doubling doses of methacholine, with no additional 
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FIG 1. The chemical structure of formoterol and salmeterol. Salmeterol is more lipophilic than formoterol. 
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FIG. 2. Salmeterol, because of its very high lipophilicity, is 
likely to enter cell membranes to a greater degree than 
formoterol, which may slow its diffusion through tissues. 
However, both sahneterol and formoterol are present in 
the cell membranes, which also could work as a depot of 
drug, explaining the long duration of action (redrawn 
from Anderson. Agents Action Suppl. 1993; 43: 253-269.) 
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FIG. 3. The shift in methacholine responsiveness after 
treatment with formoterol or salmeterol (data for placebo 
day is subtracted from each active treatment), shown as 
doubling doses of methacholine (DD). Formoterol causes 
a greater shift of methacholine responsiveness than 
salmeterol in these asthma patients, proving higher 
efficacy in vivo in man. (From Palmqvist et al. Am J 
Respir Crit Care Med 1999; 160: 244-249, with 
permission.) 
effect when the dose was increased to 500 pg. In contrast, 
formoterol showed dose-related protective effects of at least 
4.7 doubling doses, with no evidence of a maximum being 
reached after administration of 120 pg. The higher maximal 
efficacy of formoterol compared with salmeterol was 
associated with a slightly higher tremor score on the days 
formoterol treatment was given (formoterol, 120 pg, vs. 
salmeterol, 500 pg). This study confirmed the findings of 
the in vitro models that salmeterol is a partial agonist in 
relation to formoterol in human airways in vivo (42,52-55). 
Although the clinical relevance of the differences in 
efficacy between formoterol and salmeterol remains un- 
clear, several theoretical consequences of using a partial 
agonist have been noted. Firstly, it is possible that, in some 
patients, a full agonist is required to have sufficient clinical 
effect. Several such cases have been described in asthma 
(56), but it is still not clear how common this problem is in 
larger groups of asthmatic patients, or whether such cases 
can be found in a population with COPD. 
Secondly, a partial agonist (e.g. salmeterol) could 
theoretically block the bronchodilating effects of a fuller 
agonist (e.g. salbutamol) (55). However, one study pub- 
lished as an abstract found no such blocking effect of 
salmeterol on fenoterol-induced bronchoprotection (57). 
Furthermore, in patients with acute exacerbations of 
asthma treated regularly with salmeterol, the bronchodilat- 
ing effect of salbutamol is maintained compared with 
patients not treated with salmeterol, again arguing against 
any blocking effect of salmeterol on the bronchodilating 
effects of a full agonist in the clinical situation (58). It 
therefore seems likely that patients treated regularly with 
the partial j&agonist salmeterol still have enough spare p2- 
receptors on the smooth muscle for rescue &agonists to 
have sufficient effect. 
Thirdly, it may be hypothesized that a full agonist would 
be more effective in patients with severe asthma, and 
perhaps also in patients with severe COPD. However, no 
study with sufficient size and power has evaluated whether 
there are any differences between formoterol and salmeterol 
in their ability to effectively treat such patient populations. 
Conclusions 
Bronchodilators, such as anticholinergics and &-agonists, 
are clearly beneficial in the treatment of COPD, and 
evidence is emerging to suggest that long-acting &agonists 
may have additional benefits (1). Importantly, the two 
available long-acting &agonists, formoterol and salmeter- 
01, have quite different pharmacological properties. For- 
moterol has a faster onset of action than salmeterol, but the 
two compounds have a similar duration of effect. For- 
moterol also has greater efficacy than salmeterol (Fig. 1). 
The pharmacology of formoterol suggests that it may be 
beneficial as rescue medication in COPD, as has already 
been shown in asthma (59). Further studies are required to 
evaluate the clinical relevance of the pharmacological 
differences between formoterol and salmeterol in patients 
with COPD. 
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